LEADER 03390nam 2200505 450 001 9910420949803321 005 20210215212559.0 010 $a981-15-7716-1 024 7 $a10.1007/978-981-15-7716-1 035 $a(CKB)4100000011457769 035 $a(DE-He213)978-981-15-7716-1 035 $a(MiAaPQ)EBC6351759 035 $a(PPN)250221535 035 $a(EXLCZ)994100000011457769 100 $a20210215d2020 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDevelopment of selective DNA-interacting ligands $eunderstanding the function of non-canonical DNA structures /$fSefan Asamitsu 205 $a1st ed. 2020. 210 1$aSingapore :$cSpringer,$d[2020] 210 4$dİ2020 215 $a1 online resource (XIII, 111 p. 68 illus., 56 illus. in color.) 225 1 $aSpringer Theses 311 $a981-15-7715-3 327 $a1. General Introduction -- 2. Sequence-specific DNA alkylation and transcriptional inhibition by long-chain hairpin pyrrole?imidazole polyamide?chlorambucil conjugates targeting CAG/CTG trinucleotide repeats -- 3. Ligand-Mediated G-Quadruplex Induction in a Double-Stranded DNA Context by Cyclic Imidazole/Lysine Polyamide -- 4. Simultaneous Binding of Hybrid Molecules Constructed with Dual DNA-Binding Components to a G-Quadruplex and Its Proximal Duplex. 330 $aThis book addresses the development of both DNA-sequence-selective and DNA-form-selective ligands, with the aim of creating potential molecular probes and therapeutic agents for non-canonical DNA structure-caused human diseases. Over the past two decades, the structural diversity of DNA forms has been proven to have profound implications in various biological, neurological, and pharmacological events. In response, researchers have since made tremendous efforts to obtain highly active drugs interacting with disease-related non-canonical DNA structures. These drugs, however, have not yet been approved for clinical use. One obstacle impeding their clinical application has to do with selectivity. This book focuses on secondary DNA structures formed by trinucleotide repeat sequences (?hairpin form?) or guanine-rich sequences (?G-quadruplex form?), both of which are pathological molecules for neurodegenerative diseases and/or cancer. Most importantly, it contends that a particular secondary structure of DNA in the context of the human genome can be targeted with a minimal affinity to other DNA structures by means ofcareful and rational ligand design. This approach opens an avenue to the development of highly selective drugs or diagnostic chemical tools for human diseases. Readers who want to know how synthetic ligands can be designed to selectively target a certain DNA molecule will find this book highly informative. . 410 0$aSpringer theses. 606 $aDNA-ligand interactions 606 $aBioorganic chemistry 606 $aGenetics 615 0$aDNA-ligand interactions. 615 0$aBioorganic chemistry. 615 0$aGenetics. 676 $a572.864 700 $aAsamitsu$b Sefan$0947010 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910420949803321 996 $aDevelopment of selective DNA-interacting ligands$92139645 997 $aUNINA